Akebia Therapeutics Inc (NASDAQ:AKBA) reported US net product revenues of $12 million, exceeding their guidance of $10 to $11 million for the first quarter. The company has commercial contracts in ...

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo ...

Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is ...

Akebia Therapeutics AKBA shares increased by 12.6% to $2.77. The company's market cap stands at $723.6 million. As per the press release, Q1 earnings came out today. Losers ...

Akebia Therapeutics AKBA is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript May 8, 2025 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.03.

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

Akebia Therapeutics (AKBA) reported its Q1 2025 earnings, surpassing expectations with an EPS of $0.03 against a forecast of -$0.05. Revenues climbed to $57.3 million, beating the projected $44.38 ...